Anapneo Therapeutics will be awarded $250,000 to continue its work towards enabling an investigational new drug application and begin Phase I clinical trials for a compound designed to target a mechanism of respiratory regulation, treating both obstructive and central sleep apneas.
“This investment process provides a compelling opportunity for experiential learning to our students that participate as venture associates,” said Scott Meadow, clinical professor of entrepreneurship and member of the Shultz Innovation Fund Steering Committee. “The caliber of their work and level of professionalism in their presentations to the advisory committee is representative of the program’s growth and impact across our campus.”
